| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
The active form of cefcapene pivoxil hydrochloride, cefcapene acid, exerts its antibacterial activity by binding to one or more of the penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the transpeptidase activity of PBPs, preventing the cross-linking of peptidoglycan units, which are essential components of the bacterial cell wall. As a third-generation cephalosporin, cefcapene demonstrates enhanced activity against Gram-negative bacteria compared to earlier generation cephalosporins. The prodrug form, cefcapene pivoxil hydrochloride, is designed to improve oral bioavailability by enhancing intestinal absorption.
|
|---|---|
| ln Vitro |
Cefcapene pivoxil hydrochloride is active against both Gram-positive and Gram-negative bacteria. As a third-generation cephalosporin, it exhibits a wide spectrum of antibacterial activity. The compound's in vitro activity is characterized by its ability to inhibit bacterial cell wall synthesis through binding to penicillin-binding proteins. It has been studied for potential applications in dermatological conditions such as palmoplantar pustulosis (PPP). The active form, cefcapene acid, is responsible for the bactericidal activity against susceptible bacterial strains.
|
| ln Vivo |
When administered orally to mice at a dose of 100 mg/kg for four days, cefcarpine hydrochloride hydrate is effective against invasive BLNAR strains in the lungs; peak antibiotic concentrations in the mice's blood are estimated to occur between 30 and 120 minutes after gavage, reaching 2μg/ml [3].
In vivo, cefcapene pivoxil hydrochloride functions as a prodrug that is converted to its active form, cefcapene acid, after oral administration. The pivalate ester prodrug design enhances oral bioavailability by facilitating absorption from the gastrointestinal tract. Once absorbed, the compound is hydrolyzed to release the pharmacologically active cefcapene acid, which then exerts its antibacterial effects. This prodrug strategy allows for effective oral administration of the third-generation cephalosporin. |
| Enzyme Assay |
Cefcapene pivoxil hydrochloride is a prodrug that requires in vivo hydrolysis to become pharmacologically active. The compound's activity is assessed by measuring its conversion to cefcapene acid and the subsequent inhibition of bacterial cell wall synthesis. As a β-lactam antibiotic targeting penicillin-binding proteins (PBPs), its binding affinity can be evaluated using competitive binding assays with radiolabeled penicillin. The compound's stability and conversion kinetics can be studied in vitro using simulated physiological conditions.
|
| Cell Assay |
Cellular assays for cefcapene pivoxil hydrochloride are conducted using standard microbiological techniques with bacterial cultures. The compound's antibacterial activity is evaluated by determining the minimum inhibitory concentration (MIC) against various bacterial strains. Because it is a prodrug, assays may also assess the conversion of the prodrug to its active form, cefcapene acid, in cellular or enzymatic systems. The compound's ability to inhibit bacterial cell wall synthesis is assessed by measuring bacterial growth inhibition.
|
| Animal Protocol |
Animal/Disease Models: 4weeks old female C57BL/6J mice, BSG bacterial suspension (1×109 CFU) [3]
Doses: 100 mg/kg Route of Administration: Oral; 100 mg/kg; 4 days Experimental Results: Inhibition of influenza virus Haemobacilli colonize mouse lungs. In vivo animal model experiments for cefcapene pivoxil hydrochloride involve oral administration to evaluate its pharmacokinetic properties and efficacy. The prodrug is absorbed from the gastrointestinal tract and hydrolyzed to release the active cefcapene acid. Animal studies typically measure plasma concentrations of both the prodrug and the active metabolite, as well as assess antibacterial efficacy in infection models. Such studies are essential for understanding the compound's bioavailability and therapeutic potential. |
| ADME/Pharmacokinetics |
Cefcapene pivoxil hydrochloride is an orally bioavailable compound designed to improve the pharmacokinetic properties of cefcapene. The pivalate ester prodrug form enhances intestinal absorption, allowing for effective oral administration. After absorption, the prodrug is hydrolyzed in vivo to release the active cefcapene acid. This prodrug strategy is commonly employed to improve the oral bioavailability of drugs that would otherwise have poor absorption.
|
| Toxicity/Toxicokinetics |
Cefcapene pivoxil hydrochloride is generally well-tolerated as a cephalosporin antibiotic. Common adverse effects associated with cephalosporins include gastrointestinal disturbances, hypersensitivity reactions (particularly in patients with penicillin allergy), and potential effects on gut flora. As the compound contains a pivalate ester moiety, prolonged use may be associated with decreased carnitine levels.
|
| References |
|
| Additional Infomation |
Cefcapene pivoxil hydrochloride hydrate is the hydrated hydrochloride form of Cefcapene pitavaate, a prodrug belonging to the third-generation cephalosporins with antibacterial activity. Upon oral administration of Cefcapene pivoxil hydrochloride hydrate, the ester bond breaks, releasing the active ingredient Cefcapene.
Cefcapene Pivoxil Hydrochloride (CAS# 147816-24-8) is an orally bioactive third-generation cephalosporin antibiotic. It is the pivalate ester prodrug form of cefcapene, designed to be hydrolyzed in vivo to release the active cefcapene acid. The compound has a molecular formula of C₂₃H₂₈N₅O₆S₂·HCl·H₂O and a purity of >98% (HPLC). It is intended for research use only and has been studied for applications including palmoplantar pustulosis (PPP). |
| Molecular Formula |
C23H30CLN5O8S2
|
|---|---|
| Molecular Weight |
604.09
|
| Exact Mass |
621.132
|
| CAS # |
147816-24-8
|
| Related CAS # |
Cefcapene pivoxil hydrochloride;147816-23-7;Cefcapene pivoxil;105889-45-0
|
| PubChem CID |
5282437
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.47 g/cm3
|
| Boiling Point |
888.4ºC at 760 mmHg
|
| Melting Point |
158-164ºC
|
| Flash Point |
491.1ºC
|
| Vapour Pressure |
3.51E-32mmHg at 25°C
|
| LogP |
3.706
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
40
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC/C=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C.O.Cl
|
| InChi Key |
LUXIJPQYUCFVAL-XRLCNELCSA-N
|
| InChi Code |
InChI=1S/C23H29N5O8S2.ClH.H2O/c1-5-6-12(13-9-38-21(24)26-13)16(29)27-14-17(30)28-15(11(7-34-22(25)33)8-37-18(14)28)19(31)35-10-36-20(32)23(2,3)4;;/h6,9,14,18H,5,7-8,10H2,1-4H3,(H2,24,26)(H2,25,33)(H,27,29);1H;1H2/b12-6-;;/t14-,18-;;/m1../s1
|
| Chemical Name |
2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;hydrate;hydrochloride
|
| Synonyms |
S 1108; S-1108; Cefcapene Pivoxil Hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~200.93 mM)
H2O : ~1 mg/mL (~1.61 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.34 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6554 mL | 8.2769 mL | 16.5538 mL | |
| 5 mM | 0.3311 mL | 1.6554 mL | 3.3108 mL | |
| 10 mM | 0.1655 mL | 0.8277 mL | 1.6554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
